PPIs For Infants: FDA Summons Advisory Panel, But Industry Unenthusiastic
This article was originally published in The Pink Sheet Daily
Executive Summary
In this instance, FDA seems more interested than the sponsors in a potential market expansion.
You may also be interested in...
Infant GERD Studies For PPIs Need Narrower Populations, Advisory Committee Says
FDA's Gastrointestinal Drugs Advisory Committee reaches broad agreement that the pathophysiology of GERD is not the same in infants as it is in adults, although a few are vocal that it is in fact the same.
Infant GERD Studies For PPIs Need Narrower Populations, Advisory Committee Says
FDA's Gastrointestinal Drugs Advisory Committee reaches broad agreement that the pathophysiology of GERD is not the same in infants as it is in adults, although a few are vocal that it is in fact the same.
Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership
TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions